Aurobindo gets US FDA nod for Cefprozil tabs
In a development that paves the way for Aurobindo Pharma to enter the USD 80 million market in the US for antibiotic Cefzil, the Indian drug maker today said it has received USFDA nod for its Cefprozil tablets.
By PTI |
MUMBAI: In a development that paves the way for Aurobindo Pharma to enter the USD 80 million market in the US for antibiotic Cefzil, the Indian drug maker today said it has received USFDA nod for its Cefprozil tablets.
The generic version of the brand 'Cefzil' is manufactured and sold by Bristol-Myers Squibb, Aurobindo informed the BSE.
Aurobindo Pharma has got the approval for Cefprozil tablets -- a second generation cephalosporin antibiotic -- in two strengths of 250 and 500 mg, it added.
Cefprozil is mostly used to treat upper, lower respiratory tract infections and skin infections.
Aurobindo already has a significant market share in this segment/product range in several markets across the world.
Start a SIP with as low as ₹500 with ET Money App!
Download
The Economic Times News App for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.
The Economic Times News App for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.
ADVERTISEMENT
